Hyperphosphatemia is a complication of reduced kidney functions and limit for renoprotection

Authors

DOI:

https://doi.org/10.22141/2307-1257.9.1.2020.196916

Keywords:

hyperphosphatemia, chronic kidney disease, phosphate binders, sevelamer hydrochloride

Abstract

Hyperphosphatemia in patients with chronic kidney disease (CKD) is an important complication of impaired renal function and is associated with negative clinical consequences such as cardiovascular calcification, bone disease and secondary hyperparathyroidism, which leads to a worsening of cardiovascular di­sease and mortality. The purpose of this review was to discuss the management of hyperphosphatemia in CKD. The following topics are considered: phosphorus homeostasis, diagnosis of hyperphosphatemia, the effectiveness of modern dietary and pharmacological treatment using phosphate binders.

Downloads

Download data is not yet available.

References

Shaman AM, Kowalski SR. Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi Pharm J. 2016 Jul;24(4):494-505. doi: 10.1016/j.jsps.2015.01.009.

Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018 May;93(5):1060-1072. doi: 10.1016/j.kint.2017.11.036.

Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Hemodial Int. 2006;10(3):225–234. doi: 10.1111/j.1542-4758.2006.00100.x.

Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial. 2007;20(4):295–301. doi: 10.1111/j.1525-139X.2007.00309.x.

Berndt T, Thomas LF, Craig TA, et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A. 2007;104(26):11085–11090. doi: 10.1073/pnas.0704446104.

Nishi Y, Fujimoto S, Sasaki M, et al. Role of mitochondrial phosphate carrier in metabolism-secretion coupling in rat insulinoma cell line INS-1. Biochem J. 2011;435(2):421–430. doi: 10.1042/BJ20101708.

Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):257–264. doi: 10.2215/CJN.05040610.

Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol. 2007;69:341–359. doi: 10.1146/annurev.physiol.69.040705.141729.

O'Donovan RM, Widnell CC, Chen TC, Puschett JB. Parathyroid hormone transport effects and hormonal processing in primary cultured rat proximal tubular cells. Biochem J. 1993;293 ( Pt 2)(Pt 2):377–380. doi: 10.1042/bj2930377.

Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–435. doi: 10.1359/JBMR.0301264.

Ketteler M, Wüthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J. 2013;6(2):128–136. doi: 10.1093/ckj/sfs173.

National Kidney Foundation. Phosphorus and Your CKD Diet. 2019. Available from: https://www.kidney.org/atoz/content/phosphorus.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1–59. doi: 10.1016/j.kisu.2017.04.001.

Ivanov DD, Pirig LA. Commentary on the KDIGO Guideline on the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD, 2018. Kidneys. 2018;3:88-90. doi: 10.22141/2307-1257.7.3.2018.140205.

Clegg DJ, Hill Gallant KM. Plant-based diets in CKD. CJASN. 2019;14(1):141-143. doi: 10.2215/CJN.08960718.

Banerjee T, Liu Y, Crews DC. Dietary Patterns and CKD Progression. Blood Purif. 2016;41(1-3):117–122. doi: 10.1159/000441072.

Moorthi RN, Armstrong CL, Janda K, Ponsler-Sipes K, Asplin JR, Moe SM. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. Am J Nephrol. 2014;40(6):582–591. doi: 10.1159/000371498.

Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(3):620–629. doi: 10.2215/CJN.04620510.

Gorelova EA, Chernysheva NN, Kotenko ON, Shutov EV. Contemporary opportunities for using phosphate binders in dialysis patients. Clinical Nephrology. 2017;(1):71-80.

D'Alessandro C, Piccoli GB, Cupisti A. The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol. 2015;16:9. doi: 10.1186/1471-2369-16-9.

Barreto FC, Barreto DV, Massy ZA, Drüeke TB. Strategies for Phosphate Control in Patients With CKD. Kidney Int Rep. 2019;4(8):1043–1056. doi: 10.1016/j.ekir.2019.06.002.

Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226. doi: 10.1186/1471-2369-14-226.

Spaia S. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia. 2011;15(Suppl 1):22–26.

Komaba H, Wang M, Taniguchi M, et al. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Clin J Am Soc Nephrol. 2017;12(9):1489–1497. doi: 10.2215/CJN.13091216.

Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438–441. doi: 10.1038/sj.ki.5002059.

Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130–1137. doi: 10.1038/sj.ki.5002466.

St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51(3):445–454. doi: 10.1053/j.ajkd.2007.12.002.

Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24(1):278–285. doi: 10.1093/ndt/gfn488.

Cozzolino M, Rizzo MA, Stucchi A, Cusi D, Gallieni M. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther Adv Chronic Dis. 2012;3(2):59–68. doi: 10.1177/2040622311433771.

Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286–291. doi: 10.2215/CJN.05420709.

Downloads

Published

2021-09-08

How to Cite

Kushnirenko, S. (2021). Hyperphosphatemia is a complication of reduced kidney functions and limit for renoprotection. KIDNEYS, 9(1), 39–46. https://doi.org/10.22141/2307-1257.9.1.2020.196916

Issue

Vol. 9 No. 1 (2020)

Section

Looking at the problem

License

Copyright (c) 2020 S.V. Kushnirenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.